Last reviewed · How we verify
Placebo (for rivastigmine)
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in rivastigmine clinical trials (Alzheimer's disease, Parkinson's disease dementia, or Lewy body dementia).
At a glance
| Generic name | Placebo (for rivastigmine) |
|---|---|
| Also known as | Placebo |
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Placebo is administered in randomized controlled trials to serve as a comparator against the active drug (in this case, rivastigmine). Any observed effects are attributable to the placebo effect—psychological and physiological responses to the expectation of treatment rather than to any direct molecular action. This allows researchers to isolate the true efficacy of the active drug.
Approved indications
- Control arm in rivastigmine clinical trials (Alzheimer's disease, Parkinson's disease dementia, or Lewy body dementia)
Common side effects
Key clinical trials
- CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (PHASE3)
- Rivastigmine for Antimuscarinic Delirium (PHASE2)
- Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (PHASE2)
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
- A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease (PHASE3)
- Safety and Efficacy of AR1005 in Patients with Lewy Body Disease (PHASE2)
- Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) (PHASE4)
- Cognitive Decline in Non-demented PD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for rivastigmine) CI brief — competitive landscape report
- Placebo (for rivastigmine) updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI